← Back to Search

Virus Therapy

poly ICLC for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 20 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Poly ICLC may stop the growth of liver cancer by blocking blood flow to the tumor. Giving the drug directly into the arteries around the tumor may kill more tumor cells. Giving cyclophosphamide and radiation therapy together with poly ICLC may be an effective treatment for liver cancer. PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide, radiation therapy, and poly ICLC together and to see how well they work in treating patients with unresectable, recurrent, primary, or metastatic liver cancer.

Eligible Conditions
  • Breast Cancer
  • Hepatocellular Carcinoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: poly ICLCExperimental Treatment4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
poly ICLC
2003
Completed Phase 2
~190
hepatic artery embolization
2014
Completed Phase 3
~160
3-dimensional conformal radiation therapy
2007
Completed Phase 3
~2690

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
448 Previous Clinical Trials
66,629 Total Patients Enrolled
Andrew N. de la Torre, MDStudy ChairUMDNJ University Hospital / St Joseph Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled
~3 spots leftby Nov 2025